Followers | 2543 |
Posts | 250732 |
Boards Moderated | 34 |
Alias Born | 05/06/2014 |
Sunday, July 05, 2015 3:16:44 AM
By Nicole Gray | July 1, 2015
Dive Brief:
According to IMS data, doctors are writing less than 500 scripts per week for MannKind/Sanofi's inhaled insulin product Afrezza.
As TheStreet notes, Afrezza is even underperforming Pfizer's Exubera at this point, which was launched in 2006 and taken off the market in just one year.
MannKind has asserted that Afrezza is superior to Exubera in every way, and Sanofi executives have insisted—including to this publication—that a turnaround is in the cards.
Dive Insight:
Although MannKind has asserted that Afrezza is superior to Exubera in every way, the numbers tell a different story. While Afrezza only launched in the first quarter of this year, uptake has been anemic, based on the available data.
It helps, however, to look back at all of the commentary surrounding the failure of Pfizer's Exubera.
In 2008, Lutz Heinemann, PhD, published an article deconstructing that product flop and landed on two important factors—the large size of the Exubera device, which made it indiscreet (a no-no in the diabetes marketplace) and challenging dosing.
But despite the fact that MannKind addressed those problems with a smaller delivery device and an easier calculation methodology, there are still challenges, including the fact that patients must undergo a lung function test before being eligible to use Afrezza—a speedbump to be sure.
When BioPharma Dive reached out to a prescribing physician, who preferred to speak anonymously, the physician said, "I would not write it for two reasons:
1) The Exubera problem with the lungs and Afrezza's boxed warning regarding the same issue, and
2) What a pain it is trying to change a patient from the needle-based insulin to inhaled insulin because of dosing. A mistake in equivalency can mean hypoglycemia. I imagine that's why most doctors will not switch patients. The only time I would consider prescribing Afrezza would be for a new patient that I can get used to it slowly, or someone who is very scared of needles."
At this early stage, MannKind and Sanofi have obviously not declared Afrezza a failure. In fact, in a recent exclusive interview with BioPharma Dive, Sanofi's head of U.S. pharmaceuticals told us that Afrezza was off to a "solid start" despite the numbers.
"[T]he strategy here is targeted and focused, and that's important because we need to educate the specialists and high-prescribing physicians for appropriate usage of their medicine," said Jez Moulding. "In terms of access, we've secured third-tier benefit in a number of plans. We'll be launching print and direct-to-consumer promotion in the next few weeks, and we'll be launching a 12-unit cartridge later in Q3."
The companies have yet to throw in the towel on the product (publicly, anyways) and are ramping up DTC marketing efforts. But it seems like it may be an uphill battle at this point.
UPDATE: We have been receiving some very impassioned feedback regarding this post. To be clear: We do not hold any stakes in any companies that we cover. Furthermore, BioPharma Dive recognizes that it is entirely possible that Afrezza sales will pick up in the wake of DTC marketing efforts, as Sanofi's Moulding predicted to us in our interview. But only time will tell, and at this juncture, we are reporting on the few data that are available.
Recommended Reading
thestreet.com: MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin
http://www.biopharmadive.com/news/sanofimannkind-might-be-facing-a-major-flop-with-afrezza-inhaled-insulin/401602/
Recent MNKD News
- MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update • GlobeNewswire Inc. • 05/08/2024 08:18:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:11:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:05:42 PM
- MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease • GlobeNewswire Inc. • 05/06/2024 10:05:00 AM
- MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024 • GlobeNewswire Inc. • 05/01/2024 08:00:00 PM
- MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases • GlobeNewswire Inc. • 04/30/2024 10:05:00 AM
- MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease • GlobeNewswire Inc. • 04/29/2024 10:05:00 AM
- MannKind Repays Certain Debt Obligations • GlobeNewswire Inc. • 04/03/2024 10:00:00 AM
- MannKind Announces CFO Transition • GlobeNewswire Inc. • 03/26/2024 08:05:00 PM
- INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps • GlobeNewswire Inc. • 03/11/2024 10:05:00 AM
- MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8 • GlobeNewswire Inc. • 03/05/2024 11:05:00 AM
- MannKind Corporation Announces Participation at Upcoming Conferences • GlobeNewswire Inc. • 03/04/2024 06:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:05:20 PM
- MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update • GlobeNewswire Inc. • 02/27/2024 09:00:00 PM
- MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024 • GlobeNewswire Inc. • 02/20/2024 11:00:00 AM
- MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza® • GlobeNewswire Inc. • 02/15/2024 11:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 11:06:28 AM
- MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million • GlobeNewswire Inc. • 01/02/2024 11:05:00 AM
- MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 12/28/2023 11:00:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM